Efficacy of Curcumin in Oral Submucous Fibrosis

NCT ID: NCT03511261

Last Updated: 2018-04-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine whether the formulations of curcumin will effect the clinical signs and symptoms and histopathological features in patients with clinical stage 2 oral submucous fibrosis (OSMF).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

200 clinical stage 2 OSMF patients selected randomly by simple random technique with clinically \& histopathologically confirmed diagnosis are divided into 4 groups with 50 patients each.

In Group 1 patients are given 10% of curcumin mucoadhesive gel and are instructed to use it topically twice daily making it a daily dose of 1gm.

In Group 2 patients are given 500mg of curcumin capsules and are instructed to take 2 capsules twice daily making a daily dose of 1gm.

In Group 3 patients will be given 5% of curcumin mucoadhesive gel and will be instructed to use it topically twice daily \& 250mg of curcumin capsules to be taken twice daily making it a daily dose of 1gm.

Group 4 is considered as control group and provided with formulations without the active drug.

The mean scores of 4 groups will be statistically tested using Anova technique.

The differences in clinical parameters at 15 days, 1 month, 3 months \& clinical \& histopathological paramerters at 6 months will be compared between groups 1, 2, 3 \& 4 by using students 't' test \& correlation is also used for knowing the association of variables.

For all tests, a 'p' value of 0.05 or less will be utilized for statistical significance.

Other non parametric tests can also be applied where ever necessary for data analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oral Submucous Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

four groups, each group with different formulations.
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants
single blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

10%Curcumin mucoadhesive gel

Drug: Curcumin arm Curcumin10% mucoadhesive gel

Group 1 patients:

Drug : 10% curcumin mucoadhesive gel usage : Topical application Frequency : Twice daily Duration : 6 months

Group Type ACTIVE_COMPARATOR

10% Curcumin mucoadhesive gel

Intervention Type DRUG

Group 1 10%of mucoadhesive gel for topical application two times per day.

Curcumin capsules 500mg

Group 2 patients:

Drug : curcumin 500 mg capsules usage : oral intake Frequency : Twice daily Duration : 6 months

Group Type ACTIVE_COMPARATOR

Curcumin capsules 500mg

Intervention Type DRUG

Group 2 curcumin 500 mg capsules for oral intake two times per day

5% Curcumin gel+Curcumin capsules 250mg

Group 3 patients:

Drug: 5% Curcumin mucoadhesive gel \& Curcumin capsules 250mg usage : Topical application and oral intake Frequency : Twice daily Duration : 6 months

Group Type ACTIVE_COMPARATOR

5% curcumin mucoadhesive gel + Curcumin capsules 250 mg

Intervention Type DRUG

Group 3 5% curcumin mucoadhesive gel topical application two times per day + curcumin 250 mg capsules for oral intake two times per day

Placebo capsules

Group 4 patients Drug: Placebo capsules usage : oral intake Frequency : Twice daily Duration : 6 months

Group Type PLACEBO_COMPARATOR

Placebo capsule

Intervention Type DRUG

Group 4 placebo capsules for oral intake two times per day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

10% Curcumin mucoadhesive gel

Group 1 10%of mucoadhesive gel for topical application two times per day.

Intervention Type DRUG

Curcumin capsules 500mg

Group 2 curcumin 500 mg capsules for oral intake two times per day

Intervention Type DRUG

5% curcumin mucoadhesive gel + Curcumin capsules 250 mg

Group 3 5% curcumin mucoadhesive gel topical application two times per day + curcumin 250 mg capsules for oral intake two times per day

Intervention Type DRUG

Placebo capsule

Group 4 placebo capsules for oral intake two times per day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

curcuminoid curcuminoid curcuminoid non curcuminoid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 200 clinical stage 2 OSMF patients

Exclusion Criteria

* Clinical stage 1 \& 3 OSMF patients, oromucosal disorders with clinical features same as OSMF, patients who are under treatment, clinically diagnosed cases not ready for incisional biopsy, patients suffering from medically compromised conditions.
Minimum Eligible Age

14 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

H.K.E.S's S.Nijalingappa Institute of Dental Science and Research

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Syeda Arshiya Ara

Professor & Research scholar

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Syeda Arshiya Ara, MDS

Role: PRINCIPAL_INVESTIGATOR

HKE'S S.N Institute of dental sciences & research center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

HKE'S S.N Institute of dental sciences & research center

Kalaburagi, Karnataka, India

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

India

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jayashree Mudda, MDS

Role: CONTACT

+919741804012

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jayashree Mudda, MDS

Role: primary

+919741804012

References

Explore related publications, articles, or registry entries linked to this study.

Hazarey VK, Sakrikar AR, Ganvir SM. Efficacy of curcumin in the treatment for oral submucous fibrosis - A randomized clinical trial. J Oral Maxillofac Pathol. 2015 May-Aug;19(2):145-52. doi: 10.4103/0973-029X.164524.

Reference Type BACKGROUND
PMID: 26604488 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HKESSNDCG/OMR/2014/CT1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Quercetin in Treatment of Periodontitis
NCT05928546 NOT_YET_RECRUITING PHASE1